Allist(SH:688578) Xin Lang Cai Jing·2026-01-15 06:22Core Viewpoint - The stock price of Ailis has experienced a decline of 3.84% year-to-date, with a notable drop of 3.89% over the last five trading days, indicating a bearish trend in the market [2]. Company Overview - Ailis Pharmaceutical Technology Co., Ltd. was established on March 22, 2004, and went public on December 2, 2020. The company is primarily engaged in the research, production, and sales of innovative drugs [2]. - The main revenue source for Ailis is drug sales, accounting for 99.93% of total revenue, with promotional services contributing 0.06% and other sources at 0.00% [2]. Financial Performance - For the period from January to September 2025, Ailis reported a revenue of 3.733 billion yuan, representing a year-on-year growth of 47.35%. The net profit attributable to shareholders was 1.616 billion yuan, reflecting a 52.01% increase compared to the previous year [2]. - Since its A-share listing, Ailis has distributed a total of 653 million yuan in dividends [3]. Shareholder and Market Activity - As of September 30, 2025, the number of Ailis shareholders increased by 46.82% to 19,100, while the average circulating shares per person decreased by 31.89% to 23,551 shares [2]. - The stock's trading activity showed a net outflow of 14.83 million yuan from main funds, with significant buying and selling activity from large orders [1].